Compare CABO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | MYGN |
|---|---|---|
| Founded | 1980 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.1M | 625.5M |
| IPO Year | N/A | 1995 |
| Metric | CABO | MYGN |
|---|---|---|
| Price | $135.20 | $7.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $126.00 | $11.82 |
| AVG Volume (30 Days) | 153.1K | ★ 1.0M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,524,897,000.00 | $825,300,000.00 |
| Revenue This Year | N/A | $0.10 |
| Revenue Next Year | N/A | $5.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.21 |
| 52 Week Low | $96.67 | $3.76 |
| 52 Week High | $384.11 | $15.47 |
| Indicator | CABO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 46.44 |
| Support Level | $128.12 | $7.15 |
| Resistance Level | $137.91 | $7.43 |
| Average True Range (ATR) | 6.41 | 0.28 |
| MACD | 3.06 | -0.03 |
| Stochastic Oscillator | 85.46 | 21.20 |
Cable One Inc. is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. From a product standpoint, the majority of revenue comes from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols. Cable One Inc. owns its telecommunications infrastructure.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.